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To the Editor: I read with great interest the recent paper
by Kutner et al.1 on the effect of Hurricane Katrina and the
mortality of dialysis patients. To be sure, as noted by Kutner
et al., ‘each disaster may present a different set of circum-
stances and challenges that will require unanticipated
response efforts’.1 I, hereby, would like to make an additional
comment on disaster-related education for patients. What
should we teach patients? The education program for the
primary management of dialysis2 at home or nearby clinics
might be a possible useful topic for countries where machines
are easily available and the general populations are well
educated. However, for the poor countries, is this really
useful?
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Dr Wiwanitkit is concerned that, in the event of a disaster,
dialysis patients in poor countries may lack opportunities
to go to another location for dialysis, as well as resources to
manage dialysis in the home setting.1 These difficulties
highlight the more general point that poor patients are
likely to be especially vulnerable in a disaster, as Abdel-
Kader and Unruh2 have emphasized. For all patients,
possible disaster scenarios should be discussed, and there
should be a detailed disaster plan that is repeatedly
reviewed and practiced. Each patient should have a
‘survival kit’ that contains a list of the patient’s medications
and information about the specific treatment prescription,
information needed by medical relief workers. It is
especially important that patients receive information
about following strict fluid restriction and emergency diet
policy when the availability of dialysis treatments is limited
for a period of time.3 Sever et al.3 have also recommended
that patients store potassium exchange resins as a way to
prevent hyperkalemia when dialysis treatment cannot be
obtained in the initial days after a disaster.
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To the Editor: We are pleased that Isakova et al.1 have
generated the momentum for long-awaited randomized trials
on phosphorus management in patients with chronic kidney
disease. We fully agree that these are long overdue. Treatment
of millions of patients worldwide, following the Kidney
Disease Outcome Quality Initiative guidelines,2 is based
on experimental and observational data, rather than on
prospective trials. Predictably, but somewhat disappointingly,
Isakova et al. rebut the concept of a placebo-controlled
randomized controlled trial of phosphorus binders in
hemodialysis patients. They argue this would be considered
unethical, given the wide acceptance of current practice
guidelines for maintaining serum phosphate levels between
3.5 and 5.5 mg/dl.1 Would it not make more sense, when
designing these pivotal trials, to challenge these targets?
First, phosphate level targets refer to predialysis concen-
trations and do not take into account the sawtooth pattern of
phosphorus concentrations. The time-averaged phosphorus
exposure in hemodialysis patients is about 30% lower than
that suggested by predialysis phosphorus concentrations.
Second, although observational data unequivocally demon-
strate associations between high phosphorus and adverse
outcomes, numerous interventional studies in, for example,
diabetes or with erythropoietin therapy have shown that
‘normalization’ does not equal the optimal therapeutic
target.3,4 Third, availability of calcimimetics obviates the
need for phosphate binder therapy to control secondary
hyperparathyroidism. Finally, treat-to-target trials likely
require a combination of several phosphorus binders, thereby
introducing heterogeneity in treatment effects, and thus
jeopardizing the safety evaluation of individual phosphate
binders.5
When looking for the truth about phosphate control, we
might need to dare and ‘violate’ phosphorus targets in
randomized trials.
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We thank Meijers and Evenepoel1 for their comments in
‘Targeting hyperphosphatemia: truth or dare.’ We agree
that the most desirable study of phosphorus binders on
dialysis is a blinded, placebo-controlled randomized trial.
We also agree that challenging existing paradigms is
essential, especially when those paradigms themselves are
based largely on expert opinion, as in the case for serum
phosphate targets on dialysis. Unfortunately, however,
practical considerations must often prevail over ideal
theory to force compromises in the interest of progress.
In our opinion, the use of phosphorus binders on dialysis
is one example where such concessions may need to be
made. We would eagerly support and participate in a
double-blinded placebo-controlled study if it was proven
that recruitment and retention of participants was feasible
in the real world. We are skeptical, however, given the
widespread view among nephrologists that control of
phosphate is the most important aspect of the manage-
ment of mineral metabolism on dialysis. This attitude
would lead to preferential withdrawal of participants from
the placebo arm in the event of severe hyperphosphatemia.
With limited research resources and numerous questions
to be answered, the risk of failure of the ‘perfect’
phosphorus binder study on dialysis due to poor enroll-
ment, limited power, and bias would be unacceptably high.
At the crossroads of theory and practice, we believe that a
trial of more- versus less-intensive phosphate control will
present a far greater chance for operational success and
will yield critically important results that would be readily
transferable into practice. Regardless of how the nephrol-
ogy community ultimately proceeds, we are excited that
our blueprint has initiated a much-required dialogue
exemplified by the comments made by Meijers and
Evenepoel.
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To the Editor: Chevalier’s stimulating commentary1 refers to
the report that nearly 50% of children with a solitary kidney
in the setting of congenital anomalies of the kidney and
urinary tract (CAKUTs) would be receiving dialysis by
30 years of age.2
The Commentary states that the ‘fundamental differences
between the long-term outcomes of patients with congenital
solitary kidney and those of healthy adults undergoing
unilateral nephrectomy as renal transplant donors, who have
no increased risk for renal failure’ are nephron endowment
below the median, and the consequences of the compensatory
growth, such as glomerular hyperfiltration, hypertension, and
proteinuria, with the additional risks of progression, includ-
ing infection, hypoxia, and nephrotoxicity.
However, another possibility to be considered is the case
of a solitary sick kidney with genetically determined
microscopic defects such as glomerulocystic alterations,
glomerulomegalia, and small tubular ectasia belonging to
the large phenotypic spectrum of mutations in the hepato-
cyte nuclear factor-1b (HNF-1b), controlling the transcrip-
tion of genes expressed in the tubular epithelial cells,
including UMOD, Pkhd1, Pkd2, and Socs3 during kidney
development (Figure 1).3–5
A child with only one kidney and mutation in the HNF-1b
gene will have a natural story that is ineluctably irreversible and
leads to end-stage renal failure, and is therefore different from
that of other children with only one kidney or adult renal living
donors, even if they are exposed to similar risk factors.
Therefore, in the present era, looking toward biomarker
discovery and gene therapy, ‘monitoring children with
CAKUT ‘..not only..’ involves monitoring diet, y blood
pressure, etc.’,1 but also genetic evaluation including HNF-1b
gene mutation.
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